Apremilast is a novel, orally administered, targeted synthetic agent that inhibits PDE4 and secretion of various proinflammatory cytokines. Apremilast is approved for the treatment of psoriasis and psoriatic arthritis (PsA). Efficacy ans safety of apremilast were shown in the randomized, placebo-controlled clinical trials in several thousands of patients with psoriasis (ESTEEM 1, 2 ) and PsA (PALACE 1-3, ACTIVE). Unlike biologic agents, apremilast does not induce formation of neutralizing antibodies and does not increase the risk of infections.
Apremilast, targeted DMARDS, psoriasis, psoriactic arthritis.